临时ICU与常规ICU的结局比较:一项针对COVID-19所致急性呼吸窘迫综合征机械通气患者的观察性队列研究
这项单中心观察性队列研究纳入2020年3月23日至2021年4月5日期间因重症COVID-19相关ARDS接受有创机械通气的776例成人患者(常规ICU 326例,临时ICU 450例),比较30天院内死亡率及管理差异。结果显示临时ICU的30天院内未调整死亡率更高(36.0% vs 28.8%,log-rank检验p=0.023),校正混杂因素后临时ICU住院仍是死亡的独立危险因素(HR 1.4,95%CI 1.06-1.83,p=0.016)。两组28天无ICU天数、28天无呼吸机天数无差异,常规ICU再插管率和再入ICU率更高,尽管拔管后无创通气使用更多。结论提示临时ICU患者死亡率更高,尽管两区域对循证管理依从性均高。
要点
- 临时ICU住院的机械通气COVID-19 ARDS患者30天院内未调整死亡率高于常规ICU(36.0% vs 28.8%,log-rank p=0.023)。
- 校正潜在混杂因素后,临时ICU住院为死亡的独立危险因素(HR 1.4,95%CI 1.06-1.83,p=0.016)。
- 两组28天无ICU天数(中位数6 vs 2,p=0.5)和28天无呼吸机天数(中位数8 vs 5,p=0.6)无显著差异。
- 常规ICU再插管率(18% vs 12%,p=0.029)和再入ICU率(5% vs 1.6%,p=0.004)更高,尽管拔管后无创通气使用更多(13% vs 8%,p=0.025)。
- 肺保护性通气(87% vs 85%,p=0.5)、俯卧位(76% vs 79%,p=0.4)、神经肌肉阻滞(96% vs 98%,p=0.4)及COVID-19药物治疗两组相似。
适用人群与场景
- 2020年3月23日至2021年4月5日期间在单中心学术中心住院的成人重症COVID-19患者,因急性呼吸窘迫综合征接受有创机械通气,收治于临时ICU或常规ICU。
研究设计与关键结果
- 研究类型:单中心观察性队列研究;样本量:776例(常规ICU 326例,临时ICU 450例)。
- 主要终点:30天院内未调整死亡率临时ICU 36.0% vs 常规ICU 28.8%(log-rank检验p=0.023);校正混杂因素后临时ICU住院为死亡的独立危险因素(HR 1.4,95%CI 1.06-1.83,p=0.016)。
- 次要终点:28天无ICU天数中位数临时ICU 2(IQR 0-15) vs 常规ICU 6(IQR 0-16),p=0.5;28天无呼吸机天数中位数临时ICU 5(IQR 0-15) vs 常规ICU 8(IQR 0-16),p=0.6。
- 常规ICU再插管率18% vs 临时ICU 12%(p=0.029);常规ICU再入ICU率5% vs 临时ICU 1.6%(p=0.004);拔管后无创通气使用率常规ICU 13% vs 临时ICU 8%(p=0.025)。
- 肺保护性通气使用率常规ICU 87% vs 临时ICU 85%(p=0.5);俯卧位76% vs 79%(p=0.4);神经肌肉阻滞96% vs 98%(p=0.4);COVID-19药物治疗两组相似。
证据类型、等级与局限
- 证据类型:单中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管临时ICU和常规ICU对循证管理依从性均高,临时ICU住院仍与更高的30天院内死亡风险独立相关(HR 1.4,95%CI 1.06-1.83),提示临时ICU收治的机械通气COVID-19 ARDS患者可能需要更密切的监护和资源投入。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Throughout the COVID-19 pandemic, thousands of temporary ICUs have been established worldwide. The outcomes and management of mechanically ventilated patients in these areas remain unknown.
OBJECTIVES: To investigate mortality and management of mechanically ventilated patients in temporary ICUs.
DESIGN SETTING AND PARTICIPANTS: Observational cohort study in a single-institution academic center. We included all adult patients with severe COVID-19 hospitalized in temporary and conventional ICUs for invasive mechanical ventilation due to acute respiratory distress syndrome from March 23, 2020, to April 5, 2021.
MAIN OUTCOMES AND MEASURES: To determine if management in temporary ICUs increased 30-day in-hospital mortality compared with conventional ICUs. Ventilator-free days, ICU-free days (both at 28 d), hospital length of stay, and ICU readmission were also assessed.
RESULTS: We included 776 patients (326 conventional and 450 temporary ICUs). Thirty-day in-hospital unadjusted mortality (28.8% conventional vs 36.0% temporary, log-rank test p = 0.023) was higher in temporary ICUs. After controlling for potential confounders, hospitalization in temporary ICUs was an independent risk factor associated with mortality (hazard ratio, 1.4; CI, 1.06-1.83; p = 0.016).There were no differences in ICU-free days at 28 days (6; IQR, 0-16 vs 2; IQR, 0-15; p = 0.5) or ventilator-free days at 28 days (8; IQR, 0-16 vs 5; IQR, 0-15; p = 0.6). We observed higher reintubation (18% vs 12%; p = 0.029) and readmission (5% vs 1.6%; p = 0.004) rates in conventional ICUs despite higher use of postextubation noninvasive mechanical ventilation (13% vs 8%; p = 0.025). Use of lung-protective ventilation (87% vs 85%; p = 0.5), prone positioning (76% vs 79%; p = 0.4), neuromuscular blockade (96% vs 98%; p = 0.4), and COVID-19 pharmacologic treatment was similar.
CONCLUSIONS AND RELEVANCE: We observed a higher 30-day in-hospital mortality in temporary ICUs. Although both areas had high adherence to evidence-based management, hospitalization in temporary ICUs was an independent risk factor associated with mortality.
参考来源
- Jimenez JV, Olivas-Martinez A, Rios-Olais FA, et al. Outcomes in Temporary ICUs Versus Conventional ICUs: An Observational Cohort of Mechanically Ventilated Patients With COVID-19-Induced Acute Respiratory Distress Syndrome. Crit Care Explor. 2022. PMID: 35372841. doi:10.1097/CCE.0000000000000668
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。